YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2025Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset LUNG CANCER
2025ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJCO PRECISION ONCOLOGY
2025Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitorResults in Chemistry
2025Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer LUNG CANCER
2025Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA FUTURE ONCOLOGY
2025Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A JOURNAL OF THORACIC ONCOLOGY
2025Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study JOURNAL OF CLINICAL ONCOLOGY
2025Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC CANCERS
2025First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial JOURNAL OF CLINICAL ONCOLOGY
2025Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib ANNALS OF ONCOLOGY
2025A new formula consisting of the five-factor score and earliest vasculitis damage index at diagnosis for predicting poor outcomes of antineutrophil cytoplasmic antibody-associated vasculitis FRONTIERS IN MEDICINE
2025Prognostic implication of venoarterial extracorporeal membrane oxygenation in acute myocardial infarction-related cardiogenic shockJOURNAL OF INTENSIVE CARE
2025Loss of p300 in proximal tubular cells reduces renal fibrosis and endothelial-mesenchymal transition EMBO MOLECULAR MEDICINE
2025Updates on lung cancer screening for early detection KOREAN JOURNAL OF INTERNAL MEDICINE
2025Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells CELL DEATH DISCOVERY
2025Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study JOURNAL OF THE AMERICAN HEART ASSOCIATION
2025Secretory IgA dysfunction underlies poor prognosis in Fusobacterium-infected colorectal cancer GUT MICROBES
2025Fatal air embolism during intestinal endoscopy in Kasai portoenterostomy for biliary atresia: A case report WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY
2025Pyruvate kinase M2 activation maintains mitochondrial metabolism by regulating the interaction between HIF-1α and PGC-1α in diabetic kidney disease MOLECULAR MEDICINE
2025Prediction Model for Insulin Resistance and Implications for MASLD in Youth: A Novel Marker; the Pediatric Insulin Resistance Assessment Score YONSEI MEDICAL JOURNAL
1 40 4142434445464748495051 791

Recent Submissions

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links